Research Article

Sulforaphane Attenuates Isoproterenol-Induced Myocardial Injury in Mice

Lijuan Song,¹ Mudduluri Srilakshmi,² Yi Wu,³ and T. S. Mohamed Saleem ^(2,4)

¹Department of Cardiology, The Second People's Hospital of Yunnan Province, Kunming, Yunnan 650021, China

²Annamacharya College of Pharmacy, Rajampet-516126, Andhra Pradesh, India

³Department of Cardiology, Zunyi Medical University, Guiyang, Guizhou 550001, China

⁴Department of Pharmacology, College of Pharmacy, Riyadh ELM University, P.O. Box 84891, Riyadh 11681, Saudi Arabia

Correspondence should be addressed to T. S. Mohamed Saleem; saleemcology@gmail.com

Received 11 August 2020; Revised 3 December 2020; Accepted 10 December 2020; Published 21 December 2020

Academic Editor: Atef M. Al Attar

Copyright © 2020 Lijuan Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The development of isoproterenol- (ISO-) induced oxidative stress in the myocardium results in myocardial necrosis. Sulforaphane (SFN-0.4% of sulforaphane from standardized broccoli sprout extract) possesses chemoprotective, antidiabetic, and antibacterial activities and is also active against cardiovascular-related problems due to its antioxidant properties. This study was designed to investigate the cardioprotective effect of SFN against isoproterenol-induced myocardial injury in mice. Healthy male Swiss albino mice weighing 20–30 g were used in this study. These mice were randomly divided into five groups (n = 6). All the mice in the experimental groups received isoproterenol (5 mg/kg bw, via i.p.) consecutively for 2 days. The mice were treated with SFN (4 mg/kg bw) and α -tocopherol (TCF) (10 mg/kg bw) by oral gavage for 1-7 days as pre- and posttreatment for the prophylactic and treatment groups, respectively. On day 10, the following parameters were estimated for cardioprotection. Administration of isoproterenol in mice showed an increased level of serum cardiac markers and heart mitochondrial ATPase enzymes. An increased level of myocardial thiobarbituric acid-reactive substance and decreased levels of endogenous antioxidant enzymes indicated that oxidative stress is induced by isoproterenol in the myocardium. The administration of SFN in mice restored the levels of all biochemical parameters to near-normal levels. Histopathological studies further confirmed the protective effect of sulforaphane. This study concluded that treatment with SFN boosts the endogenous antioxidant activity and prevents isoproterenol-induced myocardial injury.

1. Introduction

Ischemic heart disease (IHD) is one of the leading causes of death with high mortality and morbidity rates worldwide [1]. Patients with IHD are prone to myocardial injury, which leads to myocardial dysfunction and myocardial ischemia [2]. Although several mechanisms were documented in the pathogenesis of IHD, excessive production of reactive oxygen species (ROS) was considered a prominent mechanism during myocardial ischemia [3, 4]. Therefore, reducing ROS during myocardial ischemic injury was considered the best treatment option [4]. Isoproterenol (ISO) is a synthetic -adrenergic agonist that leads to oxidative stress, causing significant myocardial injury. Upon oxidation, ISO produces quinone which generates a number of free radicals that cause oxidative and necrotic damage in the myocardium [5]. Although treatment using modern medicine was very effective, it was associated with more side effects. Therefore, researchers have been focusing on drug discovery from natural products. Moreover, plant-based drugs are economical and also cause lesser side effects [3].

Sulforaphane (SFN) Figure 1 is a biologically active phytochemical present in many plants including some vegetables like cauliflower, broccoli, and cabbage. SFN is beneficial in reducing the risk of breast, bladder, and prostate cancers [6].

Several epidemiological studies have indicated that consumption of broccoli has a positive impact on health, many of them arbitrated by isothiocyanate SFN [7].



The development of oxidative stress through generation of free radicals has established pathogenesis mechanism for myocardial injury [3, 4]. The antioxidant potential of sulforaphane was well established and documented through several research [8, 9]. Hence, this study was carried out to determine the potential protective role of SFN through antioxidant and other protective mechanism against ISOinduced myocardial injury in mice as an animal model.

2. Materials and Methods

2.1. Drugs and Chemicals. SFN (from standardized broccoli sprout extract (0.4% of sulforaphane)) was obtained as a gift sample from Lebepur, Germany, and all chemicals purchased from Sigma-Aldrich, India, were of analytical grade.

2.2. Animals. Healthy male Swiss albino mice weighing between 20 and 30 g were used for the study. The animals were kept in sanitized polypropylene cages and in sterile paddy husk bedding in an air-conditioned room and were allowed access to a pellet diet and water ad libitum (Sainath Agency, Hyderabad). The mice were maintained at a temperature of $22 \pm 2^{\circ}$ C, relative humidity of $50 \pm 5\%$, and 12:12 h light: dark cycle. All the mice were acclimatized to the laboratory conditions for 7 days before the actual study. The animals were divided into experimental and control groups. All the studies conducted were approved by the Institutional Animal Ethics Committee (IAEC/ANCP/2018-19/15).

2.3. Induction of Isoproterenol-Induced Myocardial Injury in *Mice* [10]. After a week of acclimatization, the animals were randomly divided into 5 groups with 6 mice in each group.

Group 1. Served as normal control and the mice received distilled water (10 ml/kg) through oral route.

Group 2. The mice received isoproterenol (ISO) 5 mg/kg bw, through i.p. for 2 consecutive days, and served as the toxic group.

Group 3. The mice received SFN 4 mg/kg bw, by oral gavage for 1–7 days, and served as the prophylactic group.

Group 4. The mice were treated with SFN 4 mg/kg bw, by oral gavage from days 3 up to 9, and served as the treatment group.

Group 5. The mice were treated with α -tocopherol (TCF) 10 mg/kg bw, by oral gavage from days 1 to 7, and served as the reference standard group.

Groups 3 and 5 received ISO 5 mg/kg bw, through i.p. for 2 consecutive days from day 8, and group 4 received ISO 5 mg/kg bw, through i.p. for 2 consecutive days from day 1.

2.4. Determination of Heart Weight/Body Weight Ratio. On day 10, the rats were killed by an overdose of pentobarbital (60 mg/kg bw i.p.) and the hearts were removed and weighed [11]. The wet heart weight to body weight ratio was calcu-

lated for evaluating the degree of myocardial weight gain. The heart weight/body weight ratio (mg/g) was calculated by dividing the heart weight by body weight.

2.5. Estimation of Biochemical Parameters in the Heart Homogenate. Heart tissues (0.5 g tissue) from mice were homogenized in 0.1 mM phosphate buffer, and the homogenate was used to estimate various biochemical parameters as follows.

2.5.1. Estimation of Myocardial Thiobarbituric Acid-Reactive Substances (TBARS). TBARS levels in the myocardium were measured using the method described by Okhawa et al. [12]. Briefly, 0.2 ml of homogenate was pipetted out, followed by the addition of 0.2 ml of 8.1% sodium dodecyl sulfate (SDS), 1.5 ml of 20% acetic acid (pH3.5), and 1.5 ml of 0.8% thiobarbituric acid (TBA). Boiling of the tubes was done for 60 min at 95°C and then was cooled on ice. In the tubes, double distilled water (1.0 ml) and 5.0 ml of n-butanol– pyridine (15:1 v/v) mixture were added and centrifuged at 4000 × g for 10 min. The absorbance of the colour which was developed in the organic layer was measured at 532 nm. Data are expressed as nanomoles of TBARS/gram wet weight.

2.5.2. Myocardial Reduced Glutathione (GSH). Myocardial reduced glutathione (GSH) was estimated by the method of Ellman [13]. Briefly, the reaction mixture contains 0.1 ml of supernatant, 2.0 ml of 0.3 M phosphate buffer (pH-8.4), 0.4 ml of double-distilled water, and 0.5 ml of 5,5 dithiobis 2-nitrobenzoic acid (DTNB). Incubation of reaction mixture was done for 10 minutes, and then, absorbance was measured at 412 nm. Data are expressed as mole per gram wet weight.

2.5.3. Myocardial Superoxide Dismutase (SOD). Superoxide dismutase (SOD) levels in the hearts were determined by the modified method described by Kakkar et al. [14]. Briefly, the homogenate (0.6ml) was added to sodium pyrophosphate buffer (pH—8.3), followed by the addition of 0.1ml of 186M phenazine methosulfate, 0.3ml of 300 mM nitroblue tetrazo-lium, and 0.2ml of 780 M NADH. For 90 seconds, the reaction mixture was incubated at 30°C and then, the reaction was stopped by adding 1.0ml of acetic acid, further 4.0ml of n-butanol was added, and then, the reaction mixture was centrifuged at 3000 \times g for 10min. The absorbance of the organic layer was measured at 560 nm. Data are expressed as units per milligram protein.

2.5.4. Myocardial Catalase. Catalase was estimated by the method described by Aebi [15]. Briefly, homogenate was added to a 3.0 ml cuvette containing 1.95 ml of 50 mM phosphate buffer (pH 7.0). Then, after adding1.0 ml of 30 mM hydrogen peroxide, changes in absorbance were followed for 30 s at 240 nm at an interval of 15 s. Catalase levels are expressed as units per milligram protein.

2.5.5. Estimation of Glutathione Peroxidase (GPx). Glutathione peroxidase was measured by the method described by Rotruck et al. [16]. Briefly, to 0.2 ml of tris buffer, 0.2 ml of EDTA, 0.1 ml of sodium azide, and 0.5 ml of tissue



FIGURE 2: Effect of sulforaphane on heart and body weight ratio (mg/g) (a: p < 0.001 vs. Group 1; b: p < 0.05 vs. Group 2).

homogenate were added. To this mixture, 0.2 ml of glutathione and 0.1 ml of hydrogen peroxide were added. The contents were mixed well and incubated at 37°C for 10 minutes along with a tube containing all the reagents except sample. After 10 minutes, the reaction was arrested with the addition of 0.5 ml of 10% TCA and centrifuged and the supernatant was assayed for glutathione by Ellman's method. To 2.0 ml of the supernatant, 3.0 ml disodium hydrogen phosphate solution and 1.0 ml of DTNB reagent were added. The colour developed was read at 412 nm.

2.5.6. Estimation of Protein. Protein estimation for the tissue sample of SOD and CAT was done by the method of Bradford [17]. A sample was added up to $20 \,\mu$ l with double-distilled water, $50 \,\mu$ l in sodium hydroxide, and 1 ml of Bradford reagent and kept aside for 10 min after vortexing. The absorbance was measured at 595 nm.

2.6. Estimation of Cardiac ATPase Activity. Na^+/K^+ ATPase activity, Mg^{2+} ATPase activity, and Ca^{2+} ATPase activity were estimated as described previously by Punithavathi and Prince [18]. Briefly, the mixture of 0.2 ml of heart homogenate, 1 ml of buffer, 0.2 ml of MgSO4, 0.2 ml of NaCl, 0.2 ml KCl, 0.2 ml of EDTA, and 0.2 ml of ATP were incubated at 37°C for 15 min. After 15 min, 1 ml of 10% TCA (ice-cold) was added to stop the reaction. From this, 1 ml supernatant was mixed with 4 ml of distilled water, and in this, 1 ml of 2.5% ammonium molybdate was added. This mixture was incubated at RT for 10 min, and finally, 0.4 ml of amino napthol sulfonic acid was added. OD was measured at 640 nm after 20 min by spectrophotometry.

2.7. Estimation of Cardiac Biomarkers. Lactate dehydrogenase (LDH) and creatine kinase (CK) levels in the serum were estimated by using respective kits as per the manufacturer's instruction booklet (Transasia Bio-Medicals Limited, Solan).

2.8. Histological Examination. Once the mice were sacrificed, the heart tissues were removed, washed immediately with saline, and then fixed in 10% buffered formalin. After fixation, the heart tissues were embedded in paraffin and these paraffin blocks were then cut into $5 \,\mu$ m thick sections. These sections

were stained with hematoxylin-eosin and then examined under the light microscope for histological changes.

2.9. Statistical Analysis. All values are expressed as mean \pm standard error of the mean (SEM). All the data obtained for various biochemical parameters were analyzed using oneway analysis of variance (ANOVA) followed by Dunnett's multiple comparison test (GraphPad Version 5.0, La Jolla, CA, USA). p < 0.05 was considered statistically significant.

3. Result

3.1. Effect of Sulforaphane on Heart Weight/Body Weight Ratio. After the administration of ISO in mice, the heart weight/body weight ratio was found to be 5.883 ± 0.8195 mg/g, which was significantly (p < 0.01) low compared to the mice in the control group (10.68 ± 0.6204 mg/g). A significant increase in the heart weight to body weight ratio was observed in mice treated with SFN, in both the prophylactic (9.607 ± 0.5696 mg/g) and treatment groups (10.07 ± 1.911 mg/g) and also in the α -TCF- (10.10 ± 0.2049 mg/g) treated group. The results are presented in Figure 2.

3.2. Effect of Sulforaphane on Myocardial Thiobarbituric Acid-Reactive Substances (TBARS). Mice administered with ISO showed high (p < 0.0001) levels of myocardial TBARS (345.0 ± 41.81 nmol/g wet wt) compared to the mice belonging to the control group (55.01 ± 10.59 nmol/g wet wt). A significant decrease in the TBARS levels was observed in mice treated with SFN, in both the prophylactic (147.1 ± 16.34 nmol/g wet wt) and treatment groups (166.5 ± 11.52 nmol/g wet wt) and also in the α -TCF (153.0 ± 5.61 nmol/g wet wt) treated group (Table 1).

3.3. Effect of Sulforaphane on Myocardial Glutathione (GSH). A significant (p < 0.0001) decrease in the GSH level (19.89 ± 1.702 µg/g wet wt) was observed in mice administered with ISO, compared to the control group (124.7 ± 2.442 µg/g wet wt). A significant increase in the GSH level was observed in mice treated with SFN, in both the prophylactic (125.1 ± 2.175 µg/g wet wt) and treatment groups (223.7 ± 1.635 µg/g wet wt) and also in the α -TCF- (224.0 ± 2.216 µg/g wet wt) treated group (Table 1).

Treatment group	TBARS (nmol/g wet wt)	GSH (μ g/g wet wt)	GPx (μ g/g wet wt)	SOD (IU/mg protein)	CAT (IU/mg protein)
Group 1	55.01 ± 10.59	124.7 ± 2.442	17.41 ± 0.5711	39.13 ± 5.507	270.4 ± 8.789
Group 2	345.0 ± 41.81^{a}	19.89 ± 1.702^{a}	5.766 ± 0.4945^{a}	13.70 ± 0.47^a	87.95 ± 3.591^{a}
Group 3	147.1 ± 16.3^{b}	125.1 ± 2.175^{b}	8.602 ± 0.3663^{c}	$55.69\pm5.98^{\mathrm{b}}$	308.5 ± 52.24^{d}
Group 4	166.5 ± 11.5^{b}	223.7 ± 1.635^{b}	$8.873 \pm 0.4948^{\circ}$	57.00 ± 3.5^{b}	$419.8 \pm 91.55^{\mathrm{b}}$
Group 5	153.0 ± 5.61^{b}	224.0 ± 2.216^{b}	10.94 ± 0.7333^{b}	58.53 ± 2.397^{b}	284.5 ± 27.49^{d}

TABLE 1: Effect of sulforaphane on oxidative stress and antioxidant biomarkers.

All values are expressed as mean \pm SEM. One-way ANOVA followed by Dunnett's posttest applied; ^ap < 0.0001 vs. group 1, ^bp < 0.0001 vs. group 2, ^cp < 0.001 vs. group 2, and ^dp < 0.05 vs. group 2.

3.4. Effect of Sulforaphane on Myocardial Superoxide Dismutase (SOD). Mice administered with ISO showed a low level of SOD (13.70 \pm 0.4703 IU/mg protein) compared to mice in the control group (39.13 \pm 5.507 IU/mg protein). A significant increase in the levels of SOD was observed in mice treated with SFN in both the prophylactic (55.69 \pm 5.988 IU/mg protein) and treatment groups (57.00 \pm 3.505 IU/mg protein) and also in the α -TCF- (58.53 \pm 2.397 IU/mg protein) treated group (Table 1).

3.5. Effect of Sulforaphane on Myocardial Catalase (CAT). A significant decrease in the level of CAT (87.95 ± 3.591 IU/mg protein) was observed in mice administered with ISO compared to the mice in the control group (270.4 ± 8.789 IU/mg protein). A significant increase in the levels of CAT was observed in mice treated with SFN, in both the prophylactic (308.5 ± 52.24 IU/mg protein) and treatment groups (419.8 ± 91.55 IU/mg protein) and also in the α -TCF- (284.5 ± 27.49 IU/mg protein) treated group (Table 1).

3.6. Effect of Sulforaphane on Myocardial Glutathione Peroxidase (GPx). Mice administered with ISO showed a low (p < 0.0001) level of GPx ($5.766 \pm 0.4945 \,\mu$ g/g wet wt) compared to those in the control group ($17.41 \pm 0.5711 \,\mu$ g/g wet wt). A significant increase in the GPx level was observed in mice treated with SFN, in both the prophylactic ($8.602 \pm 0.3663 \,\mu$ g/g wet wt) and treatment groups ($8.873 \pm 0.4948 \,\mu$ g/g wet wt) and also in the α -TCF- ($10.94 \pm 0.733 \,$ $3 \,\mu$ g/g wet wt) treated group (Table 1).

3.7. Effect of Sulforaphane on Mitochondrial Enzymes (Table 2)

3.7.1. Effect on Na⁺/K⁺ ATPase. The level of Na⁺/K⁺ ATPase (0.6176 \pm 0.1496) was significantly (p < 0.004) low in mice administered with ISO when compared to the mice in the control group (1.441 \pm 0.1400). A significant increase in the levels of Na⁺/K⁺ ATPase was observed in mice treated with SFN, in both the prophylactic (1.087 \pm 0.1221) and treatment groups (1.217 \pm 0.2120) and also in the α -TCF- (1.473 \pm 0.1366) treated group.

3.7.2. Effect on Mg^{2+} ATPase. A significant (p < 0.001) increase in the level of Mg^{2+} ATPase (3.492 ± 0.3425) was observed in mice administered with ISO when compared to the mice in the control group (2.780 ± 0.2605). A significant decrease in the levels of Mg^{2+} ATPase was observed in mice treated with SFN, in both the prophylactic (2.470 ± 0.3532)

TABLE 2: Effect of sulforaphane on mitochondrial ATPase enzymes.

Treatment group	Na ⁺ -K ⁺ ATPase ¹	Mg ²⁺ ATPase ¹	Ca ²⁺ ATPase ¹
Group 1	1.441 ± 0.14	2.780 ± 0.26	1.257 ± 0.13
Group 2	0.6176 ± 0.15^a	3.492 ± 0.34	2.089 ± 0.28^b
Group 3	1.087 ± 0.12	$2.470\pm0.35^{\rm c}$	$1.397\pm0.16\pm$
Group 4	$1.217\pm0.21^{\rm c}$	2.236 ± 0.09^d	$1.239\pm0.16^{\rm c}$
Group 5	1.473 ± 0.14^d	1.825 ± 0.04^{c}	1.190 ± 0.26^{c}

All values are expressed as mean ± SEM. One-way ANOVA followed by Dunnett's posttest applied; ${}^{a}p < 0.0001$ vs. group 1, ${}^{b}p < 0.05$ vs. group 1, ${}^{c}p < 0.05$ vs. group 2, and ${}^{d}p < 0.01$ vs. group 2 (1moles of pi liberated/min/mg protein).

TABLE 3: Effect of sulforaphane on mitochondrial ATPase enzymes.

Treatment group	LDH (IU/l)	CK (IU/l)
Group 1	53.97 ± 12.90	22.22 ± 3.036
Group 2	151.1 ± 11.42^{a}	122.7 ± 19.63^{a}
Group 3	42.63 ± 8.096^{b}	67.93 ± 18.29
Group 4	28.59 ± 10.78^{b}	$61.52 \pm 21.25^{\circ}$
Group 5	$63.57 \pm 18.51^{\mathrm{b}}$	$58.88 \pm 7.408^{\circ}$

All values are expressed as mean + SEM. One-way ANOVA followed by Dunnett's posttest applied; ${}^{a}p < 0.0001$ vs. group 1, ${}^{b}p < 0.001$ vs. group 2, and ${}^{c}p < 0.05$ vs. group 2.

and treatment groups (2.236 \pm 0.09049) and also in the α -TCF- (1.825 \pm 0.03871) treated group.

3.7.3. Effect on Ca^{2+} ATPase. The level of Ca^{2+} ATPase (2.089 ± 0.2810) was significantly (p < 0.02) increased in mice administered with ISO when compared to the mice in the control group (1.257 ± 0.1339). A significant decrease in the levels of Ca^{2+} ATPase was observed in mice treated with SFN, in both the prophylactic (1.397 ± 0.1683) and treatment groups (1.239 ± 0.1588) and also in the α -TCF-(1.190 ± 0.2595) treated group.

3.8. Effect of Sulforaphane on Serum Biomarkers (Table 3)

3.8.1. Effect on LDH. Mice administered with ISO showed increased levels of LDH ($151.1 \pm 11.42 \text{ IU/l}$), compared to the mice in the control group ($53.97 \pm 12.90 \text{ IU/l}$). A significant decrease in the levels of LDH was observed in mice treated with SFN, in both the prophylactic (42.63 ± 8.096



FIGURE 3: Light microscopy study of mouse myocardium treated with sulforaphane. Group 1: normal myocardial membrane integrity without any cell inflammation in the control group. Group 2: ISO-administered myocardial cells show degenerative changes and partial absence of the basement membrane. Groups 3 and 4: the heart tissue indicated the mild necrosis with minimal inflammatory changes (prophylactic and treatment group, respectively). Group 5: α -TCF-treated myocardium shows mild necrosis with minimal inflammatory changes.

IU/l) and treatment groups (28.59 \pm 10.78 IU/l) and also in the α -TCF- (63.57 \pm 18.51 IU/l) treated group.

3.8.2. Effect on CK. Mice administered with ISO showed increased levels of CK (122.7 ± 19.63 IU/l) compared to the mice in the control group (22.22 ± 3.036 IU/l). There was also a significant decrease in the levels of CK in mice treated with SFN, in both the prophylactic (67.93 ± 18.29 IU/l) and treatment groups (61.52 ± 21.25 IU/l) and also in the α -TCF- (58.88 ± 7.408 IU/l) treated group.

3.9. Effect of Sulforaphane on the Myocardium (Figure 3). Histopathological observations of the heart tissues reveal clear cell membrane integrity without any cell inflammation in the control group (group 1). However, degenerative changes in the myocardial tissue, a smaller number of myocardial cells, and partial absence of the basement membrane were observed in mice administered with ISO. These changes indicated subendocardial necrosis of the heart tissue (group 2). The heart tissue of mice in both the prophylactic and treatment groups indicated mild necrosis with minimal inflammatory changes. A similar kind of protective effect towards mild necrosis with minimal inflammatory changes was observed in mice treated with α -TCF (group 5).

4. Discussion

ISO, a β -adrenergic agonist, produces severe oxidative stress in the heart, which causes infarct-like damage in the myocardium. Several mechanisms were proposed for ISO-induced myocardial damage, but the production of ROS in autoxidation of catecholamines is one of the most significant causal reasons [19]. This study showed that ISO-induced severe oxidative stress generates free radicals that stimulate lipid peroxidation and results in irreversible damage to the myocardial membrane. A similar effect was evidenced when a significant increase in the levels of lipid peroxidation was observed on performing the TBARS assay. TBARS, an oxidative marker, increases during the oxidative stress causing myocardial injury, which is most likely due to autoxidation of ISO [20, 21]. When ISO-administered mice are treated with SFN, a significant decrease in the TBARS concentration is observed. This indicates that SFN protects the heart from lipid peroxidation by removing the excess free radicals generated by ISO.

Endogenous antioxidant enzymes such as GSH, GPx, SOD, and CAT contain hydroxyl radical and superoxide anions, which play a prominent role in protecting the cell membranes against oxidative stress and also prevent ROSinduced cellular damage [22]. The presence of endogenous antioxidant enzymatic defense is critical for neutralizing ROS-mediated tissue injury. The primary free radical scavenging enzymes such as SOD, CAT, and GPx represent the first line of cellular defense against oxidative injury, decomposing oxygen (O₂) and hydrogen peroxide (H2O2) before their interaction to form the more reactive hydroxyl radical [23]. SOD converts superoxide to hydrogen peroxide, and GPx and CAT are responsible for converting hydrogen peroxide to water. GSH directly reacts with free radicals or acts as an electron donor in the reduction of peroxides catalyzed by GPx [24].

When compared to the control group, the ISO-treated group showed decreased antioxidant enzyme levels. Other investigators observed similar changes in ISO-induced myocardial injury [20, 23, 25]. In this study, increased levels of GSH, GPx, SOD, and CAT, and restoration to normal levels in the SFN-treated groups indicated that SFN augmented the endogenous antioxidant enzymes in the mice myocardium.

Previous studies have found that enzymes such as LDH and CK-MB are present in the cardiac tissues and are used as a marker in cardiac tissue damage. Further investigations have also revealed that the levels of cardiac markers increased in ISO-treated subjects indicating that degenerative changes take place in cardiac tissues [22, 26]. When the myocardial cells containing LDH and CK are damaged due to altered myocardial cell metabolism and insufficient oxygen supply, this results in leakage of these enzymes into the bloodstream [19, 27, 28]. In this study, we observed that the level of serum markers decreased and was restored to the near-normal level in ISO-administered mice when treated with SFN, indicating the membrane stabilization effect of SFN in the mouse myocardium. ISO generates free radicals and enhances the lipid peroxidation of cardiac tissues leading mitochondrial swelling. As a result, mitochondrial enzymes such as Na^+/K^+ , $Mg^{2+}2+$, and Ca^{2+} ATPase are released causing an imbalance of myocardial electrolytes by significantly decreasing the Na^{+}/k^{+} ATPase activity and increasing the Mg²⁺ and Ca²⁺ ATPase levels [19, 29–31]. The decreased activity of Na^+/K^+ ATPase decreases the rate of sodium efflux, thereby altering membrane permeability. Ca²⁺ ATPase is a key factor in regulating the activity of the calcium pump. Enhanced Ca² levels are observed in ISO-induced mice, which is due to the activation of adenylate cyclase by ISO. This overload of calcium in the myocardial cells during injury activates the Ca²⁺ ATPase of the membrane depleting high energy phosphate stores, thereby indirectly inhibiting Na⁺ and K⁺

transport and inactivation of Na⁺/K⁺ ATPase. The Mg²⁺ ATPase activity is involved in other energy-requiring processes in the cell, and its activity is sensitive to lipid peroxidation [19, 30, 31]. ISO-treated mice exhibited a decreased Na⁺/K⁺ ATPase activity and a significant increase in the Mg2+ ATPase and Ca²⁺ ATPase activities compared to the control group. A significant increase in the Na⁺/K⁺ ATPase activity and decrease in the Mg²⁺ and Ca²⁺ ATPase levels were observed in SFN-treated groups when compared to the ISO-treated group. These results suggest the protective effect of SFN against excessive oxidative damage of the myocardium by maintaining the membrane integrity through inhibition of lipid peroxidation in cell membranes. ISOtreated mice showed a decreased heart and body weight ratio, which might be due to reduced food and protein intake and inhibition of protein synthesis in cell necrosis or denaturation of proteins [32]. However, no significant difference was observed between the control and SFN-treated mice. A significant increase in the heart weight to body weight ratio was observed in the SFN-treated mice when compared with the ISO-treated mice. These results suggest that SFN may be protecting the heart from protein denaturation.

These biochemical reports were further supported by the histopathological studies. ISO-treated mice showed degenerative changes in the myocardium and showed a smaller number of myocardial cells and partial absence of the basement membrane and also necrosis of the cardiac tissue. This indicates a severe damage with higher magnification. SFNtreated mice showed a regenerative effect and reduced pathological changes, indicating the protective effect of SFN against ISO-induced myocardial injury.

5. Conclusion

The study suggest that SFN prevents ISO-induced myocardial injury by boosting the endogenous antioxidant activity, membrane stabilization, and restoring mitochondrial integrity. Besides, this study only confirmed the cardioprotective effects of pre- and posttreatment with SFN; therefore, further studies are required to confirm any long-term useful effects of SFN with specific molecular mechanism.

Data Availability

The data presented in this work are freely accessible to any other concerned researchers or students.

Conflicts of Interest

The author declare that there was no conflict of interest.

Authors' Contributions

TSMS contributed towards the concept, design, and statistical analysis of the research work. MS conducted the literature search, carried out experimental studies, and prepared the manuscript. LS and YW reviewed and edited the manuscript for final approval.

References

- A. E. Moran, G. A. Roth, J. Narula, and G. A. Mensah, "1990-2010 global cardiovascular disease atlas," *Global Heart*, vol. 9, pp. 3–16, 2020.
- [2] V. Sharma, R. M. Bell, and D. M. Yellon, "Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy," *Expert Opinion on Pharmacotherapy*, vol. 13, no. 8, pp. 1153–1175, 2012.
- [3] S. Shahzad, S. Mateen, P. M. Mubeena Mariyath et al., "Protective effect of syringaldehyde on biomolecular oxidation, inflammation and histopathological alterations in isoproterenol induced cardiotoxicity in rats," *Biomedicine & Pharmacotherapy*, vol. 108, pp. 625–633, 2018.
- [4] M. Wang, Y. Liu, R. Pan et al., "Protective effects of Myrica rubra flavonoids against hypoxia/reoxygenation-induced cardiomyocyte injury via the regulation of the PI3K/Akt/GSK3β pathway," *International Journal of Molecular Medicine*, vol. 43, no. 5, pp. 2133–2143, 2019.
- [5] A. I. Othman, M. M. Elkomy, M. A. El-Missiry, and M. Dardor, "Epigallocatechin-3-gallate prevents cardiac apoptosis by modulating the intrinsic apoptotic pathway in isoproterenol-induced myocardial infarction," *European Journal of Pharmacology*, vol. 794, pp. 27–36, 2017.
- [6] S. Nalini, S. C. Basha, and T. S. Saleem Mohamed, "In-vitro pharmacological evaluation of sulforaphane from Brassica oleracea," *TMR Integrative Medicine*, vol. 3, article e19012, 2019.
- [7] Y. Yagishita, J. W. Fahey, A. T. Dinkova-Kostova, and T. W. Kensler, "Broccoli or sulforaphane: is it the source or dose that matters?," *Molecules*, vol. 24, no. 19, 2019.
- [8] P. Liu, W. Wang, J. Tang, R. P. Bowater, and Y. Bao, "Antioxidant effects of sulforaphane in human HepG2 cells and immortalised hepatocytes," *Food and Chemical Toxicology*, vol. 128, pp. 129–136, 2019.
- [9] S. M. de Figueiredo, N. S. Binda, J. A. Nogueira-Machado, S. A. Vieira-Filho, and R. B. Caligiorne, "The antioxidant properties of organosulfur compounds (sulforaphane)," *Recent Patents* on Endocrine, Metabolic & Immune Drug Discovery, vol. 9, no. 1, pp. 24–39, 2015.
- [10] S. De, S. Adhikari, and T. P. A. Devasagayam, "Cardioprotective effects of an aminothiazole compound on isoproterenolinduced myocardial injury in mice," *Cell Biochemistry and Biophysics*, vol. 67, no. 2, pp. 287–295, 2013.
- [11] M. T. Saleem, M. C. Chetty, and S. Kavimani, "Antioxidants and tumor necrosis factor alpha-inhibiting activity of sesame oil against doxorubicin-induced cardiotoxicity," *Therapeutic Advances in Cardiovascular Disease*, vol. 8, no. 1, pp. 4–11, 2014.
- [12] H. Okhawa, N. Qhishi, and K. Yagi, "Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction," *Analytical Biochemistry*, vol. 95, no. 2, pp. 351–358, 1979.
- [13] G. L. Ellman, "Tissue sulfhydryl groups," Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959.
- [14] P. Kakkar, B. Das, and P. N. Viswanathan, "A modified spectrophotometric assay of superoxide dismutase," *Indian Journal of Biochemistry & Biophysics*, vol. 21, no. 2, pp. 130–132, 1984.
- [15] H. Aebi, "Catalase in vitro," in Packer L, Orlando FL (org.) Methods in Enzymology, pp. 121–126, Academic Press, New York, 1984.

- [16] J. T. Rotruck, A. L. Pope, H. E. Ganther, A. B. Swanson, D. G. Hafeman, and W. G. Hoekstra, "Selenium: biochemical role as a component of glutathione peroxidase," *Science*, vol. 179, no. 4073, pp. 588–590, 1973.
- [17] M. M. Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," *Analytical Biochemistry*, vol. 72, no. 1-2, pp. 248–254, 1976.
- [18] V. R. Punithavathi and P. S. M. Prince, "Pretreatment with a combination of quercetin and α -tocopherol ameliorates adenosine triphosphatases and lysosomal enzymes in myocardial infarcted rats," *Life Sciences*, vol. 86, no. 5-6, pp. 178–184, 2010.
- [19] H. Mert, H. Yılmaz, K. Irak, S. Yıldırım, and N. Mert, "Investigation of the protective effect of kefir against isoproterenol induced myocardial infarction in rats," *Korean Journal for Food Science of Animal Resources*, vol. 38, no. 2, pp. 259–272, 2018.
- [20] V. Manju, M. Murugesan, and R. Revathi, "Cardioprotective effect of fenugreek on isoproterenol-induced myocardial infarction in rats," *Indian journal of pharmacology*, vol. 43, no. 5, article 84957, pp. 516–519, 2011.
- [21] S. N. Goyal, C. Sharma, U. B. Mahajan et al., "Protective effects of cardamom in isoproterenol-induced myocardial infarction in rats," *International Journal of Molecular Sciences*, vol. 16, no. 11, pp. 27457–27469, 2015.
- [22] H. Wei, H. Li, S. Wan et al., "Cardioprotective effects of malvidin against isoproterenol- induced myocardial infarction in rats: a mechanistic study," *Medical Science Monitor*, vol. 23, article 902196, pp. 2007–2016, 2017.
- [23] M. I. Khalil, I. Ahmmed, R. Ahmed et al., "Amelioration of isoproterenol-induced oxidative damage in rat myocardium by Withania somnifera leaf extract," *BioMed research international*, vol. 2015, Article ID 624159, 10 pages, 2015.
- [24] M. A. Hussein, "Cardioprotective effects of astaxanthin against isoproterenol-induced cardiotoxicity in rats," *Journal of Nutrition & Food Sciences*, vol. 5, 2015.
- [25] R. Afroz, E. M. Tanvir, N. Karim et al., "Sundarban honey confers protection against isoproterenol-induced myocardial infarction in Wistar rats," *BioMed Research International*, vol. 2016, Article ID 6437641, 10 pages, 2016.
- [26] S. Nishat Fathima and S. V. Murthy, "Cardioprotective effects to chronic administration of Rosa damascena petals in isoproterenol induced myocardial infarction: biochemical, histopathological and ultrastructural studies," *Biomedical and Pharmacology Journal*, vol. 12, no. 3, pp. 1155–1166, 2019.
- [27] M. T. Saleem, M. C. Chetty, and S. Kavimani, "Putative antioxidant property of sesame oil in an oxidative stress model of myocardial injury," *Journal of cardiovascular disease research*, vol. 4, no. 3, pp. 177–181, 2013.
- [28] I. A. Paritha and C. S. Devi, "Effect of tocopherol on lipid peroxidation in isoproterenol-induced myocardial infarction in rats," *Indian Journal of Biochemistry & Biophysics*, vol. 41, pp. 369–376, 1997.
- [29] E. Brindha and M. Rajasekapandiyan, "Preventive effect of phytic acid on isoproterenol-induced cardiotoxicity in Wistar rats," *International Journal of Biomedical Sciences*, vol. 11, no. 1, pp. 35–41, 2015.
- [30] A. H. Shaik, A. K. Mohammed, M. Sammeturi, S. Y. al Omar, A. Mohammad, and L. K. Kodidhela, "Maslinic acid ameliorate electrolytes, membrane bound ATPases, antioxidants

and histopathology in isoprenaline attenuated myocardial toxicity in rats," *Journal of King Saud University-Science*, vol. 32, no. 1, pp. 1055–1059, 2020.

- [31] K. A. Bhave, P. R. Pandit, J. Ved, and G. Amonkar, "Evaluation of cardioprotective effect of metformin in isoproterenol induced myocardial injury in rats," *Indian Journal of Physiology and Pharmacology*, vol. 60, no. 4, pp. 392–402, 2016.
- [32] E. M. Prasad, R. Mopuri, M. S. Islam, and L. D. Kodidhela, "Cardioprotective effect of *Vitex negundo* on isoproterenolinduced myocardial necrosis in wistar rats: a dual approach study," *Biomedicine & Pharmacotherapy*, vol. 85, pp. 601– 610, 2017.